{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hoang TT"],"funding":["The Center for Experimental Therapeutics","Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center","Mr. William H. and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research","NCI NIH HHS","NIH","Tow Foundation","NIH NCI"],"pagination":["511-518"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10187976"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(4)"],"pubmed_abstract":["<h4>Purpose</h4>Immuno-positron emission tomography (immunoPET) combines the specificity of an antibody with the sensitivity of PET to image dysregulated pathways in cancer. This study examines the performance of immunoPET using the radioimmunoconjugate [<sup>89</sup>Zr]Zr-DFO-Panitumumab to detect epidermal growth factor receptor (EGFR) expression in an orthotopic model of bladder cancer (BCa).<h4>Procedures</h4>Expression and quantification of EGFR receptors were confirmed in four different BCa cell lines. Binding assays validated [<sup>89</sup>Zr]Zr-DFO-Panitumumab specificity for EGFR-expressing UMUC3 BCa cells. Subcutaneous and orthotopic UMUC3 xenografts were then used for PET imaging and ex vivo biodistribution of the radioimmunoconjugate. Control cohorts included non-tumor mice, <s"],"journal":["Molecular imaging and biology"],"pubmed_title":["EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors."],"pmcid":["PMC10187976"],"funding_grant_id":["R35 CA232130","P30 CA008748","R01 CA244233","R01 CA244233-01A1"],"pubmed_authors":["Viray T","Hoang TT","Tan KV","Lewis JS","Pereira PMR","Mandleywala K"],"additional_accession":[]},"is_claimable":false,"name":"EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors.","description":"<h4>Purpose</h4>Immuno-positron emission tomography (immunoPET) combines the specificity of an antibody with the sensitivity of PET to image dysregulated pathways in cancer. This study examines the performance of immunoPET using the radioimmunoconjugate [<sup>89</sup>Zr]Zr-DFO-Panitumumab to detect epidermal growth factor receptor (EGFR) expression in an orthotopic model of bladder cancer (BCa).<h4>Procedures</h4>Expression and quantification of EGFR receptors were confirmed in four different BCa cell lines. Binding assays validated [<sup>89</sup>Zr]Zr-DFO-Panitumumab specificity for EGFR-expressing UMUC3 BCa cells. Subcutaneous and orthotopic UMUC3 xenografts were then used for PET imaging and ex vivo biodistribution of the radioimmunoconjugate. Control cohorts included non-tumor mice, <s","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-05T16:14:24.438Z","creation":"2025-04-05T16:14:24.438Z"},"accession":"S-EPMC10187976","cross_references":{"pubmed":["35147837"],"doi":["10.1007/s11307-022-01708-2"]}}